SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Sana Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.30+0.03 (+1.32%)
Close on Oct 19, 2026
- Market cap
- $680.03M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
61.7%
185M of 299M shares
Institutional holders
211
34 new, 22 sold out
Net institutional buying
21M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Robert Nelsen | 46,173,125 | 15.40% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC | 31,609,175 | 14.21% | 13G (passive) amendment | Nov 12, 2024 |
| Noubar B. Afeyan, Ph.D | 25,583,551 | 13.00% | 13G (passive) amendment | Dec 31, 2023 |
| Peter Kolchinsky | 18,750,000 | 6.30% | 13G (passive) | May 14, 2026 |
| BlackRock, Inc. | 13,643,304 | 5.10% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SANA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 37,429,515 | 12.50% | $130.63M | −769 | 0.01% |
| Flagship Pioneering Inc. | 25,001,856 | 8.35% | $87.26M | – | 5.67% |
| Ra Capital Management, L.P. | 18,750,000 | 6.26% | $65.44M | New | 0.57% |
| BlackRock, Inc. | 16,675,173 | 5.57% | $58.20M | +2,434,998 | 0.00% |
| State Street Corp | 11,203,134 | 3.74% | $39.10M | +665,048 | 0.00% |
| Canada Pension Plan Investment Board | 10,218,400 | 3.41% | $35.66M | −3,500 | 0.02% |
| Vanguard Capital Management LLC | 8,375,421 | 2.80% | $29.23M | +940,697 | 0.00% |
| Bank Of America Corp /De/ | 5,748,454 | 1.92% | $20.06M | +2,801,593 | 0.00% |
| Geode Capital Management, LLC | 4,677,959 | 1.56% | $16.33M | +495,986 | 0.00% |
| Marex Group plc | 3,989,100 | 1.33% | $13.92M | −10,000 | 0.06% |
| Marshall Wace, Llp | 2,931,436 | 0.98% | $10.23M | +2,266,979 | 0.01% |
| Alphabet Inc. | 2,812,500 | 0.94% | $9.82M | – | 0.01% |
| Goldman Sachs Group Inc | 2,367,935 | 0.79% | $8.26M | −813,180 | 0.00% |
| Integral Health Asset Management, LLC | 2,000,000 | 0.67% | $6.98M | −1,200,000 | 0.28% |
| Toronto Dominion Bank | 1,972,381 | 0.66% | $6.88M | New | 0.01% |
| Vanguard Portfolio Management LLC | 1,881,689 | 0.63% | $6.57M | +174,168 | 0.00% |
| Jacobs Levy Equity Management, Inc | 1,868,718 | 0.62% | $6.52M | New | 0.02% |
| Northern Trust Corp | 1,604,084 | 0.54% | $5.60M | +125,233 | 0.00% |
| Charles Schwab Investment Management Inc | 1,379,181 | 0.46% | $4.81M | +13,033 | 0.00% |
| Woodline Partners LP | 1,317,932 | 0.44% | $4.60M | – | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 211 | 185M | 61.7% | 34 / 67 | 65 / 22 | 36M | 15M |
| Q1 2026 | 203 | 164M | 54.9% | 30 / 68 | 57 / 25 | 22M | 7M |
| Q4 2025 | 203 | 160M | 53.4% | 48 / 70 | 47 / 21 | 16M | 22M |
| Q3 2025 | 178 | 166M | 55.4% | 46 / 65 | 37 / 21 | 27M | 7M |
| Q2 2025 | 155 | 146M | 48.8% | 25 / 50 | 48 / 30 | 11M | 15M |
| Q1 2025 | 161 | 149M | 49.9% | 30 / 54 | 41 / 32 | 7M | 15M |
| Q4 2024 | 164 | 158M | 52.8% | 42 / 58 | 33 / 32 | 12M | 8M |
| Q3 2024 | 155 | 154M | 51.5% | 33 / 41 | 45 / 24 | 21M | 5M |
| Q2 2024 | 148 | 149M | 49.9% | 21 / 58 | 37 / 26 | 13M | 14M |
| Q1 2024 | 154 | 150M | 50.2% | 38 / 46 | 40 / 15 | 33M | 9M |
| Q4 2023 | 132 | 126M | 42.2% | 23 / 51 | 31 / 27 | 10M | 11M |
| Q3 2023 | 136 | 128M | 42.6% | 23 / 42 | 39 / 10 | 8M | 16M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SANA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 10,508,590 | 3.51% | $34.68M | 0.04% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,077,517 | 2.36% | $24.70M | 0.23% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 6,251,644 | 2.09% | $21.82M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,807,959 | 1.61% | $16.78M | 0.02% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 3,106,086 | 1.04% | $10.25M | 0.04% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 2,857,700 | 0.95% | $9.43M | 0.04% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 2,008,443 | 0.67% | $6.29M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,920,775 | 0.64% | $6.70M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,680,858 | 0.56% | $5.87M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,276,572 | 0.43% | $4.46M | 0.05% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,263,152 | 0.42% | $4.17M | 0.08% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 863,772 | 0.29% | $2.85M | 0.02% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 843,865 | 0.28% | $2.78M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 770,926 | 0.26% | $2.54M | 0.01% | May 31, 2026 |
| Vanguard Health Care Index Fund | 520,072 | 0.17% | $1.72M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steve Harr | President & CEO, Director | 8,960,751 | 2.99% | Mar 10, 2026 |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 183,352 | 0.06% | Aug 27, 2026 |
| Susan D. Wyrick | See Remarks | 197,241 | 0.07% | Mar 10, 2026 |
| Brian Piper | EVP, Chief Financial Officer | – | – | Feb 18, 2026 |
| Bernard J. Cassidy | EVP & General Counsel | 112,990 | 0.04% | Mar 10, 2025 |
| Hans Edgar Bishop | Director | 5,854,800 | 1.96% | Jul 7, 2026 |
| Robert Nelsen | Director, 10% owner | 10,681,240 | 3.57% | Jun 5, 2026 |
| Michelle Seitz | Director | – | – | Jun 5, 2026 |
| Richard Mulligan | Director | 2,698,121 | 0.90% | Jun 5, 2026 |
| Alise Reicin | Director | – | – | Jun 5, 2026 |
| Patrick Y. Yang | Director | 149,250 | 0.05% | Jun 5, 2026 |
| Joshua H. Bilenker | Director | 20,000 | 0.01% | Jun 5, 2026 |
| Robert L. Rosiello | Director | – | – | Jun 5, 2026 |
| Mary Agnes Wilderotter | Director | 7,106 | 0.00% | Jun 9, 2025 |
| Llc Fmr | 10% owner | 4,707,484 | 1.57% | Jan 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dhavalkumar Dhirajlal Patel EVP, Chief Scientific Officer | Aug 27, 2026 | Tax withholding | −41,158 | $4.11 | $169.16K | 183,352 |
| Dhavalkumar Dhirajlal Patel EVP, Chief Scientific Officer | Aug 26, 2026 | Option exercise | +125,000 | – | – | 224,510 |
| Hans Edgar Bishop Director | Jul 6, 2026 | Award | +6,297 | – | – | 5,854,800 |
| Hans Edgar Bishop Director | Apr 6, 2026 | Award | +7,763 | – | – | 5,848,503 |
| Steve Harr President & CEO, Director | Mar 9, 2026 | Tax withholding | −12,819 | $3.10 | $39.74K | 7,944,251 |
| Steve Harr President & CEO, Director | Mar 9, 2026 | Tax withholding | −11,526 | $3.13 | $36.08K | 7,957,070 |
| Susan D. Wyrick See Remarks | Mar 9, 2026 | Tax withholding | −3,342 | $3.13 | $10.46K | 197,241 |
| Susan D. Wyrick See Remarks | Mar 9, 2026 | Tax withholding | −1,045 | $3.10 | $3.24K | 196,196 |
| Steve Harr President & CEO, Director | Mar 7, 2026 | Option exercise | +50,000 | – | – | 7,968,596 |
| Susan D. Wyrick See Remarks | Mar 7, 2026 | Option exercise | +3,250 | – | – | 200,583 |
| Steve Harr President & CEO, Director | Mar 6, 2026 | Option exercise | +41,666 | – | – | 7,918,596 |
| Susan D. Wyrick See Remarks | Mar 6, 2026 | Option exercise | +10,416 | – | – | 197,333 |
| Susan D. Wyrick See Remarks | Mar 3, 2026 | Tax withholding | −491 | $3.91 | $1.92K | 186,917 |
| Susan D. Wyrick See Remarks | Mar 2, 2026 | Option exercise | +1,525 | – | – | 187,408 |
| Susan D. Wyrick See Remarks | Jan 5, 2026 | Tax withholding | −2,407 | $4.27 | $10.28K | 185,883 |
| Hans Edgar Bishop Director | Jan 5, 2026 | Award | +6,157 | – | – | 5,840,740 |
| Susan D. Wyrick See Remarks | Jan 2, 2026 | Option exercise | +7,500 | – | – | 188,290 |
| Susan D. Wyrick See Remarks | Dec 15, 2025 | Tax withholding | −873 | $5.22 | $4.56K | 180,790 |
| Susan D. Wyrick See Remarks | Dec 13, 2025 | Option exercise | +3,400 | – | – | 181,663 |
| Susan D. Wyrick See Remarks | Dec 4, 2025 | Tax withholding | −2,565 | $4.44 | $11.39K | 178,263 |
| Susan D. Wyrick See Remarks | Dec 3, 2025 | Option exercise | +10,000 | – | – | 180,828 |
| Hans Edgar Bishop Director | Oct 6, 2025 | Award | +5,628 | – | – | 5,834,583 |
| Hans Edgar Bishop Director | Jul 7, 2025 | Award | +7,842 | – | – | 5,828,955 |
| Susan D. Wyrick See Remarks | Jun 4, 2025 | Tax withholding | −2,567 | $2.32 | $5.96K | 167,828 |
| Susan D. Wyrick See Remarks | Jun 3, 2025 | Option exercise | +10,000 | – | – | 170,395 |
| Hans Edgar Bishop Director | Apr 7, 2025 | Award | +16,339 | – | – | 5,821,113 |
| Steve Harr President & CEO, Director | Mar 10, 2025 | Tax withholding | −12,820 | $2.56 | $32.82K | 7,876,930 |
| Susan D. Wyrick See Remarks | Mar 10, 2025 | Tax withholding | −836 | $2.56 | $2.14K | 157,395 |
| Bernard J. Cassidy EVP & General Counsel | Mar 10, 2025 | Tax withholding | −2,833 | $2.56 | $7.25K | 112,990 |
| Steve Harr President & CEO, Director | Mar 7, 2025 | Option exercise | +50,000 | – | – | 7,889,750 |
| Susan D. Wyrick See Remarks | Mar 7, 2025 | Option exercise | +3,250 | – | – | 158,231 |
| Bernard J. Cassidy EVP & General Counsel | Mar 7, 2025 | Option exercise | +11,041 | – | – | 115,823 |
| Susan D. Wyrick See Remarks | Mar 3, 2025 | Tax withholding | −490 | $2.56 | $1.25K | 154,981 |
| Susan D. Wyrick See Remarks | Mar 2, 2025 | Option exercise | +1,525 | – | – | 155,471 |
| Llc Fmr 10% owner | Jan 8, 2025 | Sale | −25,000 | $6.50 | $162.50K | 4,707,423 |
| Llc Fmr 10% owner | Jan 8, 2025 | Sale | −1,000 | $7.26 | $7.26K | 4,541,511 |
| Llc Fmr 10% owner | Jan 8, 2025 | Sale | −164,912 | $6.71 | $1.11M | 4,542,511 |
| Llc Fmr 10% owner | Jan 8, 2025 | Sale | −100,000 | $6.11 | $611.00K | 4,732,423 |
| Hans Edgar Bishop Director | Jan 6, 2025 | Award | +14,285 | – | – | 5,804,774 |
| Susan D. Wyrick See Remarks | Jan 2, 2025 | Tax withholding | −1,566 | $1.65 | $2.58K | 153,946 |
| Susan D. Wyrick See Remarks | Jan 2, 2025 | Option exercise | +5,000 | – | – | 155,512 |
| Hans Edgar Bishop Director | Oct 7, 2024 | Award | +5,938 | – | – | 5,790,489 |
| Richard Mulligan Director | Sep 25, 2024 | Sale(10b5-1 plan) | −150,000 | $3.89 | $583.50K | 2,698,121 |
| Richard Mulligan Director | Sep 24, 2024 | Sale(10b5-1 plan) | −150,000 | $4.08 | $612.00K | 2,848,121 |
| Hans Edgar Bishop Director | Jul 5, 2024 | Award | +4,911 | – | – | 5,784,551 |
| Hans Edgar Bishop Director | Apr 5, 2024 | Award | +2,774 | – | – | 5,779,640 |
| Patrick Y. Yang Director | Mar 8, 2024 | Sale | −25,000 | $9.45 | $236.25K | 149,250 |
| Robert Nelsen Director, 10% owner | Feb 8, 2024 | Buy | +363,637 | $5.50 | $2.00M | 10,667,387 |
| Robert Nelsen Director, 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| Robert Nelsen Director, 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| ARCH Venture Fund X, L.P. 10% owner | Feb 8, 2024 | Buy | +363,637 | $5.50 | $2.00M | 10,667,387 |
| ARCH Venture Fund X, L.P. 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| ARCH Venture Fund X, L.P. 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| Kristina Burow 10% owner | Feb 8, 2024 | Buy | +363,637 | $5.50 | $2.00M | 10,667,387 |
| Kristina Burow 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| Kristina Burow 10% owner | Feb 8, 2024 | Buy | +727,272 | $5.50 | $4.00M | 12,446,022 |
| Mary Agnes Wilderotter Director | Jan 5, 2024 | Award | +1,470 | – | – | 7,106 |
| Hans Edgar Bishop Director | Jan 5, 2024 | Award | +4,901 | – | – | 5,776,866 |
| Christian Hordo EVP, Chief Business Officer | Dec 15, 2023 | Sale(10b5-1 plan) | −75,000 | $4.00 | $300.00K | 867,455 |
| Hans Edgar Bishop Director | Oct 5, 2023 | Award | +6,925 | – | – | 5,771,965 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hordo & Katharine Hordo Christian Officer | Feb 18, 2025 | 75,000 | $237.00K | Feb 18, 2025 | Founders Shares |
| Hordo & Katharine Hordo Christian Officer | Jan 16, 2025 | 75,000 | $289.50K | Jan 16, 2025 | Founders Shares |
| Hordo & Katharine Hordo Jt Ten Christian Officer | Dec 16, 2024 | 75,000 | $141.75K | Dec 16, 2024 | Founders Shares |
| Nathan Hardy Former CFO | Nov 26, 2024 | 91,607 | $229.02K | Nov 26, 2024 | Founders Stock |
| Hardy Nathan Former CFO | Nov 25, 2024 | 25,933 | $64.96K | Nov 25, 2024 | Founder Stock |
| Hardy Nathan Officer | Oct 21, 2024 | 45,796 | $180.81K | Oct 21, 2024 | Stock Option Exercise |
| Mulligan Richard Director | Sep 25, 2024 | 150,000 | $613.50K | Sep 25, 2024 | Restricted Stock Awards |
| Mulligan Richard Director | Sep 24, 2024 | 150,000 | $613.50K | Sep 24, 2024 | Restricted Stock Awards |
| Hordo & Katharine Hordo Jt Ten Christian Officer | Dec 15, 2023 | 75,000 | $299.25K | Dec 15, 2023 | Restricted Stock Awards |
| Flagship V Venturelabs RX Fund, L.P. Affiliate | Jun 7, 2023 | 39,830 | $254.51K | Jun 7, 2023 | Venture Capital Investment |
| Flagship Ventures Fund V, L.P. Affiliate | Jun 7, 2023 | 310,170 | $1.98M | Jun 7, 2023 | Venture Capital Investment |
| Flagship V Venturelabs RX Fund, L.P. affiliate | May 24, 2023 | 85,334 | $598.19K | May 24, 2023 | venture capital investment |
| Flagship Ventures Fund V, L.P. affiliate | May 24, 2023 | 85,334 | $598.19K | May 24, 2023 | Venture Capital investment |
| Flagship Ventures Fund V, L.P. affiliate | May 24, 2023 | 664,666 | $4.66M | May 24, 2023 | Venture Capital investment |